Pridopidine Phase 3 Study in Huntington's Disease

Conditions

• Huntington Disease

Eligibility Criteria

Sex

ALL

Age

23 Years - 65 Years

Healthy Volunteers

Not accepted

Interventions

• Pridopidine — DRUG
  Pridopidine hard gelatin capsule
• Placebo — DRUG
  Matched placebo hard gelatin capsule

Study Details

The goal of this clinical trial is to learn if pridopidine can slow the clinical decline of Huntington's Disease (HD) in adult participants. It will also inform about the safety of pridopidine. The main questions the study aims to answer are: Does pridopidine slow the overall worsening of HD over 1 year? Does pridopidine slow the worsening of specific aspects of HD over 1 year, namely the clinical progression, the ability to perform daily life activities (functional capacity), the mind's ability to process information (cognition), working of the muscles (motor function), and quality of life? Researchers will compare the drug pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works better than placebo to treat HD. During the first year of the study, participants will have the same chance to receive either pridopidine or placebo. Participants will: Take 1 pridopidine or placebo capsule twice daily for 12 months. Visit the clinic 6 times within 1 year for checkups and tests. All participants who complete this 1-year placebo-controlled study period will roll over into an additional 2-year study period during which all participants will receive pridopidine treatment, including participants who had received placebo during the first year. During this additional 2-year treatment period participants will visit the clinic a total of 6 times for checkups and tests.

Key Dates

First listed

May 27, 2026

Start date

Jul 1, 2026

Status verified

May 2026

Primary completion

Jun 30, 2028

Completion

Jun 30, 2030

Study Design

Enrollment

400 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Pridopidine
  During the titration period (2 weeks), pridopidine 45 mg capsules will be taken orally once daily (in the morning) for 2 weeks. Afterwards, pridopidine 45 mg capsules will be taken orally twice daily (in the morning and in the afternoon; 7-10 hours apart) for 50 weeks.
• Placebo Comparator: Placebo
  During the titration period (2 weeks), matched placebo hard gelatin capsules will be taken once daily (in the morning) for 2 weeks. Afterwards, placebo capsules will be taken twice daily (in the morning and in the afternoon; 7-10 hours apart) for 50 weeks.

Primary Outcome Measure

Change in Composite Unified Huntington's Disease Rating Scale (cUHDRS) [ Time Frame: Change from Baseline to Week 52 ]

Central Contacts

• Prilenia Medical Information
  018575745755
  [email protected]

Locations (25)

Find similar trials in Birmingham, AL

Related Studies

• Retinal Imaging in Neurodegenerative Disease
  Recruiting · Duke University · Durham, North Carolina
• Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease
  Recruiting · The University of Texas Health Science Center, Houston · Houston, Texas
• Extracellular Vesicles for HD
  Recruiting · University of Central Florida · Orlando, Florida
• NYSCF Scientific Discovery Biobank
  Recruiting · New York Stem Cell Foundation Research Institute · New York, New York